

Latent EBV and Stomach Cancer; CBCD Reviews the Association

Recent cancer genome atlas research has provided a molecular classification defining EBV-positive gastric cancer as a specific subtype. (1)

ROCHESTER, NEW YORK, UNITED STATES OF AMERICA, December 14, 2015 /EINPresswire.com/ --

“Infected with the Epstein Barr Virus (EBV)? The CBCD recommends taking [Novirin](#) or [Gene-Eden-VIR](#).” - Greg Bennett, CBCD

Recent studies have shown that the Epstein-Barr Virus (EBV) is associated with a specific subset of stomach cancers. In fact, data “suggest that EBV infection might be associated with induction of persistent gastric mucosa inflammation and subsequent carcinogenesis (beginnings of cancer).” (1) New research also suggests that that the latent EBV can cause cellular changes that become cancer in those with a healthy immune system. Dr. Eminger and colleagues wrote that “over the past few decades, cumulative research has revealed that latent EBV infection may be implicated in the pathogenesis of a heterogeneous group of lymphoproliferative disorders and malignancies occurring in both immunocompetent and immunocompromised hosts.” (2) Dr. Eminger is from the Geisinger Medical Center in Danville, Pennsylvania.

Another study showed that “infection with the Epstein-Barr (EB) virus has been

reported to be associated with various cancers, including stomach cancer ... according to these studies, the rate of infection ranges from 22.2% to 41.2%. (3) These studies are very clear. Latent EBV is associated with cancer. “Most EBV associated cancers contain viral DNA that exists predominantly as a latent infection in which only a limited set of viral genes are expressed. These latency associated genes are implicated in host-cell



The CDC notes that “Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a member of the herpes virus family. It is one of the most common human viruses. EBV is found all over the world. Most people get infected with EBV at some point in their lives.” (5) The Center for the Biology of Chronic Disease (CBCD) recommends that in light of the medical evidence, infected individuals take Novirin or Gene-Eden-VIR. The formula of these natural, antiviral supplements was designed to help the immune system target the latent EBV.

Click to learn more about [EBV symptoms](#).

The Center for the Biology of Chronic Disease (CBCD) recommends that in light of the medical evidence, individuals concerned about infection with the latent EBV take Gene-Eden-VIR or Novirin. The formula of these natural, antiviral supplements was designed to help the immune system target the latent form of the Epstein-Barr Virus.

The formula of Gene-Eden-VIR and Novirin was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Novirin formula is effective against the herpes family of viruses. The Epstein Barr Virus (EBV) is a member of the herpes family. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with the EBV ... reported a safe decrease in their symptoms following treatment with (the formula of Novirin).” (6) The study authors also wrote that, “We observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (6)

Gene-Eden-VIR and Novirin can be ordered online on their respective websites, here:

<http://www.gene-eden-vir.com>

and

<http://www.novirin.com>

Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

Some doctors argue that latent viruses are inactive, that is, they show no transcription (production of proteins) and no shedding. Since the virus is inactive it is harmless. In contrast, Dr. Tikhmyanova wrote that “Epstein-Barr Virus (EBV) persists as a latent infection in many lymphoid and epithelial malignancies, including Burkitt's lymphomas, nasopharyngeal carcinomas, and gastric carcinomas. Current chemotherapeutic treatments of EBV-positive cancers include broad-spectrum cytotoxic drugs that ignore the EBV-positive status of tumors.” (4) The evidence is building that latent viruses are active, although on a reduced scale, and are still dangerous. A paper entitled “Human Cytomegalovirus Persistence” published February 13, 2012 in the journal Cellular Microbiology, clearly says that latent viruses are active. “Both the chronic and latent states of infection contribute to HCMV persistence and to the high HCMV seroprevalence worldwide. The chronic infection is poorly defined molecularly, but clinically manifests as low-level virus shedding over extended periods of time and often in the absence of symptoms.”(7) To clarify, the expression “absence of symptoms” means

the absence of standard symptoms, which are usually associated with active infection. Also note how the paper describes viral shedding during latency.

“The results of these studies are consistent with the research conducted by the CBCD on Microcompetition, and the clinical studies on the formula of Novirin and Gene-Eden-VIR.” - Greg Bennett, CBCD

Find us on Facebook here: <https://www.facebook.com/GeneEdenVIR>

Follow us Twitter on here: @HananPolansky

All orders of these products are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1) Chen XZ1, Chen H, Castro FA, Hu JK, Brenner H. "Epstein-Barr virus infection and gastric cancer: a systematic review." *Medicine (Baltimore)*. 2015 May;94(20):e792.

<http://www.ncbi.nlm.nih.gov/pubmed/25997049>

(2) Eminger LA1, Hall LD2, Hesterman KS3, Heymann WR4. "Epstein-Barr virus: Dermatologic associations and implications: Part II. Associated lymphoproliferative disorders and solid tumors." *J Am Acad Dermatol*. 2015 Jan;72(1):21-34.

<http://www.ncbi.nlm.nih.gov/pubmed/25497918>

(3) Shinsuke Takeno, Tatsuya Hashimoto, Kenji Maki, Ryosuke Shibata, Hironari Shiwaku, Ippei Yamana, Risako Yamashita, and Yuichi Yamashita "Gastric cancer arising from the remnant stomach after distal gastrectomy: A review" - *World J Gastroenterol*. Oct 14, 2014; 20(38)

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4194557/>

(4) Tikhmyanova N1, Schultz DC, Lee T, Salvino JM, Lieberman PM. Identification of a new class of small molecules that efficiently reactivate latent Epstein-Barr Virus. *ACS Chem Biol*. 2014 Mar 21;9(3):785-95.

<http://www.ncbi.nlm.nih.gov/pubmed/24028149>

(5) CDC.com - About Epstein-Barr Virus (EBV). Last updated January 6, 2014.

<http://www.cdc.gov/epstein-barr/about-ebv.html>

(6) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013.

<http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101>

(7) Felicia Goodrum,1,2,3 Katie Caviness,3, and Patricia Zagallo1, Human Cytomegalovirus Persistence, *Cell Microbiology*. Published May

2012.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330195/#_fn_sectitle

Greg Bennett
CBCD
585-250-9999
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.
© 1995-2015 IPD Group, Inc. All Right Reserved.

